Development and validation of a high-content screening assay to identify inhibitors of cytoplasmic dynein-mediated transport of glucocorticoid receptor to the nucleus

Assay and Drug Development Technologies

Volumn 10, Issue 5, 2012, Pages 432-456

  Johnston, Paul A ^a,b   Shinde, Sunita N ^a   Hua, Yun ^a   Shun, Tong Ying ^a   Lazo, John S ^c   Day, Billy W ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; ADENOSINE TRIPHOSPHATE; APOMORPHINE; CYTOPLASMIC DYNEIN; DEXAMETHASONE; DIMETHYL SULFOXIDE; GLUCOCORTICOID NUCLEAR HORMONE RECEPTOR GREEN FLUORESCENT FUSION PROTEIN; GLUCOCORTICOID RECEPTOR; GREEN FLUORESCENT PROTEIN; HEAT SHOCK PROTEIN 90; HYBRID PROTEIN; PARTHENOLIDE; TANESPIMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BREAST ADENOCARCINOMA; CELL MIGRATION; CONTROLLED STUDY; DRUG HYDROLYSIS; HIGH CONTENT SCREENING ASSAY; HIGH THROUGHPUT SCREENING; MICROTUBULE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; STEROID BINDING;

ANIMALS; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; CYTOPLASMIC DYNEINS; DEXAMETHASONE; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; MICE; PROTEIN TRANSPORT; RECEPTORS, GLUCOCORTICOID;

EID: 84867257825     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2012.456     Document Type: Article

References (55)

1. Hirokawa N: Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 1998;279:519-526. (Pubitemid 28067273)
2. Hirokawa N, Noda Y, Tanaka Y, Niwa S: Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol 2009;10:682-696.
3. Vallee R, Williams JC, Varma D, Barnhart LE: Dynein: An ancient motor protein involved in multiple modes of transport. J Neurobiol 2003;58:189-200. (Pubitemid 38173717)
4. Vallee R, Seale GE, Tsai JW: Emerging roles for myosin II and cytoplasmic dynein in migrating neurons and growth cones. Trends Cell Biol 2009;19:347-355.
5. Vallee R, Hook P: Autoinhibitory and other autoregulatory elements within the dynein motor domain. J Struct Biol 2006;156:175-181. (Pubitemid 44486056)
6. Zhu G, Yang F, Balachandran R, Hook P, Vallee RB, Curran DP, Day BW: Synthesis and biological evaluation of purealin and analogues as cytoplasmic dynein heavy chain inhibitors. J Med Chem 2006;49:2063-2076.
7. Dujardin D, Barnhart LE, Stehman SA, Gomes ER, Gundersen GG, Vallee RB: A role for cytoplasmic dynein and LIS1 in directed cell movement. J Cell Biol 2003;163:1205-1211. (Pubitemid 38032082)
8. Greber U, Way M: A superhighway to virus infection. Cell 2006;124:741-754. (Pubitemid 43261449)
9. Luo L, Parrish CA, Nevins N, McNulty DE, Chaudhari AM, Carson JD, Sudakin V, Shaw AN, Lehr R, Zhao H, Sweitzer S, Lad L, Wood KW, Sakowicz R, Annan RS, Huang PS, Jackson JR, Dhanak D, Copeland RA, Auger KR: ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat Chem Biol 2007;3:722-726. (Pubitemid 47609114)
10. Mayer T, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ: Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999;286:971-974.
11. Sarli V, Giannis A: Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res 2008;14:7583-7587.
12. Chrousos G, Kino T: Glucocorticoid signaling in the cell. Expanding clinical implications to complex human behavioral and somatic disorders. Ann NY Acad Sci 2009;1179:153-166.
13. Huang P, Chandra V, Rastinejad F: Structural overview of the nuclear receptor superfamily: Insights into physiology and therapeutics. Annu Rev Physiol 2010;72:247-272.
14. Lu N, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA: International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev 2006;58:782-797. (Pubitemid 44833746)
15. Revollo J, Cidlowski JA: Mechanisms generating diversity in glucocorticoid receptor signaling. Ann NY Acad Sci 2009;1179:167-178.
16. Grad I, Picard D: The glucocorticoid responses are shaped by molecular chaperones. Mol Cell Endocrinol 2007;275:2-12. (Pubitemid 47260713)
17. Morishima Y, Murphy PJ, Li DP, Sanchez ER, Pratt WB: Stepwise assembly of a glucocorticoid receptor.hsp90 heterocomplex resolves two sequential ATPdependent events involving first hsp70 and then hsp90 in opening of the steroid binding pocket. J Biol Chem 2000;275:18054-18060. (Pubitemid 30414753)
18. Murphy P, Morishima Y, Chen H, Galigniana MD, Mansfield JF, Simons SS, Jr., Pratt WB: Visualization and mechanism of assembly of a glucocorticoid receptor.Hsp70 complex that is primed for subsequent Hsp90-dependent opening of the steroid binding cleft. J Biol Chem 2003;278:34764-34773. (Pubitemid 37102235)
19. Murphy P: Regulation of glucocorticoid receptor steroid binding and trafficking by the hsp90/hsp70-based chaperone machinery: Implications for clinical intervention. Leukemia 2005;19:710-712. (Pubitemid 40663088)
20. Pratt WB, Dittmar KD: Studies with Purified Chaperones Advance the Understanding of the Mechanism of Glucocorticoid Receptor-hsp90 Heterocomplex Assembly. Trends Endocrinol Metab 1998;9:244-252. (Pubitemid 28357616)
21. Pratt WB, Morishima Y, Osawa Y: The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J Biol Chem 2008;283:22885- 22889.
22. Galigniana M, Radanyi C, Renoir JM, Housley PR, Pratt WB: Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus. J Biol Chem 2001;276:14884-14889.
23. Harrell J, Murphy PJ, Morishima Y, Chen H, Mansfield JF, Galigniana MD, Pratt WB: Evidence for glucocorticoid receptor transport on microtubules by dynein. J Biol Chem 2004;279:54647-54654. (Pubitemid 40053208)
24. Owens-Grillo J, Czar MJ, Hutchison KA, Hoffmann K, Perdew GH, Pratt WB: A model of protein targeting mediated by immunophilins and other proteins that bind to hsp90 via tetratricopeptide repeat domains. J Biol Chem 1996;271: 13468-13475. (Pubitemid 26185390)
25. Hook P, Mikami A, Shafer B, Chait BT, Rosenfeld SS, Vallee RB: Long range allosteric control of cytoplasmic dynein ATPase activity by the stalk and Cterminal domains. J Biol Chem 2005;280:33045-33054. (Pubitemid 41368354)
26. Williams J, Roulhac PL, Roy AG, Vallee RB, Fitzgerald MC, Hendrickson WA: Structural and thermodynamic characterization of a cytoplasmic dynein light chain-intermediate chain complex. Proc Natl Acad Sci USA 2007;104:10028- 10033. (Pubitemid 47175257)
27. Echeverri'a P, Mazaira G, Erlejman A, Gomez-Sanchez C, Piwien Pilipuk G, Galigniana MD: Nuclear import of the glucocorticoid receptor-hsp90 complex through the nuclear pore complex is mediated by its interaction with Nup62 and importin beta. Mol Cell Biol 2009;29:4788-4797.
28. Freedman N, Yamamoto KR: Importin 7 and importin alpha/importin beta are nuclear import receptors for the glucocorticoid receptor. Mol Biol Cell 2004;15: 2276-2286. (Pubitemid 38580645)
29. Savory J, Hsu B, Laquian IR, Giffin W, Reich T, Haché RJ, Lefebvre YA: Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. Mol Cell Biol 1999;19:1025-1037. (Pubitemid 29046846)
30. Htun H, Barsony J, Renyi I, Gould DL, Hager GL: Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera. Proc Natl Acad Sci USA 1996;93:4845-4850. (Pubitemid 26162839)
31. McNally J, Muller WG, Walker D, Wolford R, Hager GL: The glucocorticoid receptor: Rapid exchange with regulatory sites in living cells. Science 2000;287: 1262-1265. (Pubitemid 30112147)
32. Walker D, Htun H, Hager GL: Using inducible vectors to study intracellular trafficking of GFP-tagged steroid/nuclear receptors in living cells. Methods 1999;19:386-393. (Pubitemid 30028597)
33. Minguez J, Giuliano KA, Balachandran R, Madiraju C, Curran DP, Day BW: Synthesis and high content cell-based profiling of simplified analogues of the microtubule stabilizer (+) -discodermolide. Mol Cancer Ther 2002;1:1305-1313.
34. Johnston P, Foster CA, Shun TY, Skoko JJ, Shinde S, Wipf P, Lazo JS: Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Assay Drug Dev Technol 2007;5:319-332. (Pubitemid 47067878)
35. Johnston P, Soares KM, Shinde SN, Foster CA, Shun TY, Takyi HK, Wipf P, Lazo JS: Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev Technol 2008;6:505-518.
36. Nickischer D, Laethem C, Trask OJ, Jr., et al.: Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2- EGFP translocation, c-Jun, and ERK activation. Methods Enzymol 2006;414: 389-418. (Pubitemid 44716234)
37. Trask OJ, Jr., Baker A, Williams RG, et al.: Assay development and case history of a 32K-biased library high-content MK2-EGFP translocation screen to identify p38 mitogen-activated protein kinase inhibitors on the ArrayScan 3.1 imaging platform. Methods Enzymol 2006;414:419-439. (Pubitemid 44716235)
38. Williams RG, Kandasamy R, Nickischer D, et al.: Generation and characterization of a stable MK2-EGFP cell line and subsequent development of a high-content imaging assay on the Cellomics ArrayScan platform to screen for p38 mitogenactivated protein kinase inhibitors. Methods Enzymol 2006;414:364-389. (Pubitemid 44716233)
39. Johnston PA, Phillips J, Shun TY, et al.: HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile Virus. Assay Drug Devel Technol 2007;5:737-750.
40. Johnston PA, Foster CA, Tierno MB, Shun TY, Brummond KM, Wipf P, Lazo JS: Characterization of the Cdc25B dual specificity phosphatase inhibitor hits identified in a high throughput screen of the NIH compound library. Assay Drug Devel Technol 2009;7:250-265.
41. Shun T, Lazo JS, Sharlow ER, Johnston PA: Identifying actives from HTS data sets, practical approaches for the selection of an appropriate HTS data processing method and quality control review. J Biomol Screening 2011;16:1-14.
42. Johnston P: Automated high content screening microscopy. In: High Content Screening. Haney S (ed.), pp. 25-42. John Wiley and Sons, Inc., Hoboken, NJ, 2008.
43. Trask O, Nickischer D, Burton A, Williams RG, Kandasamy RA, Johnston PA, Johnston PA: High-throughput automated confocal microscopy imaging screen of a kinase-focused library to identify p38 mitogen-activated protein kinase inhibitors using the GE InCell 3000 analyzer. Methods Mol Biol 2009;565: 159-186.
44. Elbi C, Walker DA, Romero G, Sullivan WP, Toft DO, Hager GL, DeFranco DB: Molecular chaperones function as steroid receptor nuclear mobility factors. Proc Natl Acad Sci USA 2004;101:2876-2881. (Pubitemid 38327704)
45. Elbi C, Walker DA, Lewis M, Romero G, Sullivan WP, Toft DO, Hager GL, DeFranco DB: A novel in situ assay for the identification and characterization of soluble nuclear mobility factors. Sci STKE 2004;238:pI10.
46. Martinez E, Hager GL: Development of assays for nuclear receptor modulators using fluorescently tagged proteins. Methods Enzymol 2006;414:37-50. (Pubitemid 44716215)
47. Galigniana M, Scruggs JL, Herrington J, Welsh MJ, Carter-Su C, Housley PR, Pratt WB: Heat shock protein 90-dependent (geldanamycin-inhibited) movement of the glucocorticoid receptor through the cytoplasm to the nucleus requires intact cytoskeleton. Mol Endocrinol 1998;12:1903-1913. (Pubitemid 28544185)
48. Czar M, Galigniana MD, Silverstein AM, Pratt WB: Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus. Biochemistry 1997;36:7776-7785. (Pubitemid 27287189)
49. Kakar M, Kanwal C, Davis JR, Li H, Lim CS: Geldanamycin, an inhibitor of Hsp90, blocks cytoplasmic retention of progesterone receptors and glucocorticoid receptors via their respective ligand binding domains. AAPS J 2006;8: E718-E728. (Pubitemid 44867025)
50. Daghestani H, Zhu G, Johnston PA, Shinde SN, Brodsky JL, Day BW: Characterization of inhibitors of glucocorticoid receptor nuclear translocation: A model of cytoplasmic dynein-mediated cargo transport. Assay Drug Dev Technol 2012;10:46-60.
51. Nasu K, Nishida M, Ueda T, Yuge A, Takai N, Narahara H: Application of the nuclear factor-kappaB inhibitor BAY 11-7085 for the treatment of endometriosis: An in vitro study. Am J Physiol Endocrinol Metab 2007;293:E16-E23. (Pubitemid 47105911)
52. Medana C, Ermondi G, Fruttero R, Di Stilo A, Ferretti C, Gasco A: Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: Thiol-mediated nitric oxide release and biological evaluation. J Med Chem 1994;37:4412-4416.
53. Rice W, Hillyer CD, Harten B, Schaeffer CA, Dorminy M, Lackey DA, 3rd, Kirsten E, Mendeleyev J, Buki KG, Hakam A, Kun E: Induction of endonuclease-mediated apoptosis in tumor cells by C-nitroso-substituted ligands of poly(ADP-ribose) polymerase. Proc Natl Acad Sci USA 1992;89:7703-7707.
54. Miglietta A, Bozzo F, Gabriel L, Bocca C: Microtubule-interfering activity of parthenolide. Chem Biol Interact 2004;149:165-173. (Pubitemid 39387218)
55. Miyata N, Gon Y, Nunomura S, Endo D, Yamashita K, Matsumoto K, Hashimoto S, Ra C: Inhibitory effects of parthenolide on antigen-induced microtubule formation and degranulation in mast cells. Int Immunopharmacol 2008;8: 874-880.